February 2, 2018
Adler closes offering $250M of 2.50% Convertible Senior Notes Due 2025
A migraine treatment focused biopharmaceutical specialist, Alder BioPharmaceuticals, has closed on Thursday previously announced underwritten offering of $250 million aggregate…